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11.1. Background
Drug-facilitated crime (DFC) is a general term that includes rape or other sexual 
assault, robbery, money extortion, as well as the deliberate maltreatment of the 
elderly or children under the influence of psychotropic substances. DFCs are criminal 
acts carried out by means of administering a substance to a person with the inten-
tion of impairing behaviour, perceptions or decision-making capacity. It also extends 
to taking advantage of an impaired person, without their consent, after their voluntary 
intake of an incapacitating substance. While the covert use of drugs to facilitate 
crime has occurred over the centuries, it has recently been highlighted by a  significant 
increase in reports of DFC worldwide. 
Psychoactive substances used in DFCs may alter the victim’s degree of conscious-
ness, state of awareness, judgement and memory. Such substances can make the 
victim vulnerable and unable to fight off their attacker. In addition, they can be used 
to sedate the victim in order to facilitate easier transport by the perpetrator.
The perpetrator of a DFC can either be a stranger or an acquaintance. Most sub-
stances used in DFCs are potent fast-acting central nervous system (CNS) depres-
sants with effects that mimic severe alcohol intoxication or general anesthesia. The 
resulting pharmacological effects may include relaxation, euphoria, lack of inhibi-
tion, amnesia, impaired perception, difficulty in maintaining balance, impaired 
speech, drowsiness, loss of motor function, vomiting, incontinence, unconsciousness 
and possibly death. This may lead police to assume that the victim was drunk rather 
than drugged and thus impact the investigation. In many instances, the perpetrator 
is well aware of the effects of the administered drug.
Drug-facilitated sexual assault (DFSA), which is a subset of DFC, occurs when a 
person (male or female) is subjected to sexual act(s) while they are incapacitated 
or unconscious due to the effect(s) of ethanol, a drug and/or other intoxicating 
substance, and as a result unable to resist or consent to such acts. Substances may 
be administered covertly to an intended victim or victims, or a perpetrator may take 
advantage of a victim after voluntary ingestion of the substance.
The use of the term “date rape” by the media in cases of sexual assault, to describe 
DFSA, may be misleading. The media has focused on only a few of the drugs such 
as Rohypnol®, GHB and ketamine that can be used in DFSA. However, there are 
many other substances that can be used to facilitate such crimes including alcohol, 
over-the-counter medicines, other psychoactive prescription drugs and illicit 
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substances. Many substances give additive depressant effects when combined with 
alcohol and may be considerably easier to obtain than those given prominence in 
the media; for example, perpetrators have been known to use their own prescription 
medicines to incapacitate others. 
The true prevalence of DFCs is unknown. Many studies suggest that fewer than 
20 per cent of sexual assaults are reported to law enforcement agencies. In DFSA 
cases the impact that central nervous system depressant drugs have on memory and 
 consciousness result in even fewer DFSAs being reported as compared to sexual 
assault not involving drugs.
Factors which complicate investigations in DFC include: 
 " Lack of experience among investigators, medical personnel, laboratories 
and prosecutors in handling in DFC cases, 
 " Lack of recognition of the crime by law enforcement agencies,
 " Delays in reporting the incident, 
 " A broad range of substances that may be used. 
Currently, no international standards are in place to facilitate the detection and 
identification of the substances that may be used in DFC. In addition there is no 
uniform system for defining and collecting statistical data on DFC. 
Several countries have reported an increase in the non-medical use of psychotropic 
substances and expressed concern about the abuse of these substances. The United 
Nations Commission on Narcotic Drugs adopted a resolution 53/7 (53rd session, 
2010) on “International cooperation in countering the covert administration of 
 psychoactive substances related to sexual assault and other criminal acts” which 
inter alia requested UNODC to analyse the phenomenon of drug-facilitated sexual 
assault or other criminal acts and develop guidelines for forensic analysis to identify 
the presence of psychoactive substances. As a follow up to this resolution, UNODC 
organized a meeting of international subject-matter experts on 23-25 March 2011 
at the UNODC Headquarters in Vienna to develop these guidelines. 
1.2. Purpose and scope of the manual
This manual is one of a series of UNODC LSS publications on guidelines, best 
practices and recommended methods of analysis of drugs under international control 
and related substances. Developed as a practical guide of best practices and logical 
procedures, this manual will assist in the investigation, analytical detection and 
prosecution in DFC cases. It is intended for worldwide use with the aim of  improving 
investigational and analytical capabilities. Specifically, it provides guidance to:
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 " Investigators and medical professionals as to requirements for successful 
evidence collection including sample collection and storage. 
 " Analytical toxicologists to carry out analysis of these substances and 
 interpret results in cases of DFCs. 
The manual outlines the investigative and analytical challenges related to DFC 
and emphasizes the importance of evidence collection as a basis for further investi-
gation. In this regard, it also provides recommendations on practical tools for the 
collection of evidence. Further, it addresses the limitations of the analytical toxico-
logical  investigation and other issues that may impact the interpretation of results. 
Detailed consideration is given to all analytical aspects important in the detection 
and identi fication of substances and interpretation of results in the context of DFSA 
cases. References to validated methods for analysis of blood, urine and hair samples 
are given in bibliography. The manual emphasizes the importance of  collaboration 
of all those involved in the investigation and the importance of  collecting 
consistent data.
While the emphasis of this document is on DFSA, similar considerations apply in 
the investigation of other drug-facilitated crimes (DFC), such as robbery, money 
extortion, human trafficking and the abuse of the elderly, children and mental 
health patients. 

5There are a number of investigative and analytical challenges that may occur in any 
case in which drugs were used to facilitate the crime. An awareness and apprecia-
tion of these challenges is important for a successful investigation.
When the victim of a DFC is unclear about the events leading up to the assault 
because of the amnesiac effects of the drug(s) administered, it may lead to a delay 
in reporting the incident, if it is even reported at all. A considerable amount of time 
may be spent trying to fill in memory gaps by speaking with friends who were with 
the victim or even with the assailant, if the person is known to the victim. The 
possibility that the victim may have been completely unconscious when the crime 
occurred and, thus has no idea that he or she was assaulted, complicates reporting 
even further. It is unlikely in these cases, for the victim ever to report the crime, 
unless something arouses his or her suspicion. As an investigator, it is important to 
recognize and be sensitive to these reasons for the delay in reporting of DFCs.
Once individuals report that they feel they may have been a victim of DFSA, it is 
critical that appropriate biological specimens, for example urine (see section 3), are 
quickly collected. Some of the drugs used are detectable in urine only for short 
periods of time post-administration, some for less than one day post-exposure, while 
others may be detectable in urine for four or more days after the alleged offence, 
depending of the screening and confirmation methods. A delay of just one or two 
hours in the collection of a blood specimen for toxicological testing may lead to an 
administered substance being missed.
The investigator must obtain complete information about any substances voluntarily 
ingested by the complainant. This includes an estimate of the amount of alcohol 
consumed in the period leading up to the alleged assault, any recreational drugs 
taken, as well as prescription or over-the-counter medications that may have been 
recently used. It is vital that the victim tells the truth about this information if a 
prosecution is to succeed. Assertions about substances used may be verified by 
analysing for metabolites, specific markers, or segmental analysis of hair collected 
at least one month after the alleged incident. 
Many investigations have failed to unveil complete information on ingested drug(s) 
due to the apprehension of some victims that admission to the voluntary use of a 
drug, such as cannabis, could prejudice the outcome of the investigation or court 
proceedings. Investigators must assure the victim that such information is needed 
to help explain the incapacitation that was experienced. Investigators must also 
remember that even if the victim voluntarily consumed the drugs that in the event 
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incapacitated him or her, it should not be misconstrued that the person did so with 
the intent of becoming a victim of crime.
In addition to the collection of biological evidence from the complainant, evidence 
should also be collected from the crime scene(s). All evidence should be collected 
using proper chain-of-custody procedures in order to ensure their authenticity, 
 integrity and traceability.
The CNS depressants that may be used in DFSA present many analytical challenges. 
Many are highly potent and hence are given in very low doses. The drugs that may 
be encountered are not limited to illicit drugs, but include prescription and over-
the-counter medications that may be readily available to most perpetrators. The low 
doses that may be used as well as the different physicochemical properties of many 
of these compounds often make it difficult for laboratories to detect their presence 
using routine analytical methodologies, hence more sensitive methodology and 
instrumentation has to be applied. Furthermore, investigators, health-care workers 
and laboratory personnel may not be aware of the range of drugs that may be used 
to facilitate crimes. This may result in the analysis focusing on only a few suspected 
drugs and missing the drug that was actually used. There are over 50 drugs known 
to have been used in DFSA, and each year new drugs are introduced that may be 
encountered in such cases. The large number of compounds that may be encountered 
presents a serious challenge to the toxicology laboratory charged with performing 
sensitive, comprehensive screening tests for all of these drugs. A thorough investiga-
tion of the circumstances of each case can provide the laboratory with information 
as to the drugs to focus on for a better probability of success.
It is important to remember that many of the drugs that feature in DFSA, including 
alcohol, may give rise to similar clinical symptoms in a complainant. Therefore, it 
is not possible to conclude that incapacitation reported by a complainant is due to 
a particular substance without evidence that the substance (or a specific marker/
metabolite) is present in a sample from the complainant. Additionally, since most 
drugs are metabolized and eliminated from the body at different rates, it should 
never be assumed that a negative toxicological finding is proof that an incapacitating 
drug was not present at the time of the alleged assault.
The analysis of samples collected during investigation of DFSA must be performed 
by well-trained staff in an appropriate forensic toxicology laboratory. Such analyses 
are not routine in most forensic toxicology laboratories and generally require 
advanced instrumentation that may not be available in all laboratories. It is important 
that selective and appropriately validated analytical procedures are employed that 
are capable of detecting these drugs and their metabolites with the highest possible 
sensitivity. It is therefore advisable that properly collected and stored evidential 
specimens are sent to an adequately equipped analytical toxicology laboratory 
instead of immediate and partial analysis carried out in a laboratory that does not 
have the adequate analytical capacity for this purpose. 
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Different analytical strategies may be required for different specimens (urine, blood, 
saliva, scene residues, vomit, stained clothing, and hair) submitted for analysis. For 
example, urine samples may require hydrolysis in order to facilitate detection of 
metabolites excreted as conjugates, while analysis of blood and hair may focus more 
on the parent drug.
Finally, the interpretation of the toxicological findings can be challenging. Identifica-
tion of any drug or metabolite in a biological specimen is generally proof of expo-
sure, but simply detecting a compound at best may substantiate other evidence as 
to possible incapacitation at the time of the alleged offense. Further, given the 
individual variations in the rate at which drugs are metabolized, it is usually difficult 
to assess the dose or the exact time of exposure. Information from other sources 
such as scene residues can provide strong corroborative evidence. On the other hand, 
failure to detect a drug or metabolite, i.e. a negative result, does not always mean 
that the drug was not ingested. Some compounds (for example GHB, ethanol) occur 
naturally in the human body, so quantitative information is vital in the interpretation 
of results.

9The initial interview of the alleged victim, subsequent examination by a health-care 
professional and systematic collection of biological specimens are important stages 
in the first phase of a DFSA investigation (see annex 4, “Example of information 
collection worksheet for DFSA cases”). While the alleged victim’s care is of prime 
importance; focus should also be on preserving evidence of the crime.  Evidence of 
sexual assault (vaginal and anal swabs for spermatozoa and eventual DNA testing, 
description and photos of haematoma, evidence of other injury) must be carefully 
collected and documented by the healthcare professional. It is important that the 
health-care professional has the proper forensic training and is qualified to collect 
evidence that will be used in criminal cases. 
Biological evidence should be collected as soon as possible using an adequate DFSA 
evidence collection kit, and should be accompanied by proper chain of custody 
documentation. Biological samples must be collected ideally before any medication 
is administered to the victim, but if this is not possible, all such medications must 
be documented. Specimens should be properly labelled with the date and time of 
collection and the collector’s initials. Collected specimens should be immediately 
sealed and stored securely. A major advancement in investigating DFSA is to allow 
that a urine sample is taken from the complainant as soon as the incident is reported: 
this could be done by trained police officers.
While each case has its own history and peculiarities that may warrant the use of 
one specimen over another, urine is usually the specimen of choice for a toxicologi-
cal investigation of suspected DFSAs. Compared to blood, urine samples allow for 
a longer window of detection of drugs and metabolites. These specimens should be 
collected and refrigerated as quickly as possible. The sooner a urine specimen is 
obtained after the alleged event, the greater the chance of detecting drugs that are 
quickly eliminated from the body. 
3.1. Evidence collection kits
While DFCs that do not involve a sexual assault may require collection of only a 
urine and blood sample, sexual assault cases may require the collection of more 
evidence. It is imperative that medical facilities that are responsible for initiating 
the collection of biological samples from a possible victim of crime have appropriate 
evidence collection kits available, including appropriate urine and blood tubes for 
specimen collection for toxicological analysis. 
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Sexual assault evidence kits should contain:
 " Evidence collection instructions and directives
 " Unique identification information for each kit and for each item in the kit
 " Self-sealing bags for each exhibit
 " Evidence seal
 " Paper bags for clothing and objects
 " Paper (covering floor surface) to collect evidence while complainant 
undresses
 " 5 ml blood tubes with sodium fluoride/potassium oxalate preservatives 
 (recommended concentrations for NaF 2.5 g/l and potassium oxalate 2 g/l) 
for toxicological analysis (blood tubes should be completely filled)
 " Buccal swabs or 5 ml blood tube with potassium-EDTA for genetic analysis
 " Two sterile plastic 30 ml urine containers without preservatives 
 " Sterile DNA free swabs for body cavities and surfaces (for example to 
sample for traces of sperm, blood and saliva)
 " Physiological saline solution for vaginal or anal rinsing and/or wet sterile 
swabs, if needed
 " Wooden applicators to collect evidence from under nails
 " Gloves, hair net and mask for collector
 " Chain of custody form, with medical report and standard questionnaire for 
the health-care professional (complainant’s full name, date and time of 
sampling, date and time of alleged assault, use of drugs and medication a 
week prior to the assault, date and time of last consented sexual relations, 
time of previous urination, etc.) 
The chain of custody of evidence must be initiated and specimens should be submit-
ted to a forensic toxicology laboratory that is capable of screening for a wide range 
of compounds at high sensitivity. If local regulations require the hospital’s own 
laboratory to conduct some of the analyses, duplicate samples of the hospital-tested 
samples should be collected, if possible, for submission to the forensic laboratory. 
However, these preliminary/screening assays that may be performed at the hospital 
should be as wide and inclusive as possible with due consideration of the specificity 
and the detection limits of the screening technique. 
3.2. Sample transfer and storage 
Evidence collected from the victim of a suspected DFC must be properly sealed 
and secured. Biological specimens should be stored at 2-8 °C to help prevent 
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degradation. Specimens should be transported refrigerated to the laboratory as 
quickly as possible; in any event minimizing the time they are kept at temperatures 
above 25 °C. 
3.3 Biological samples and sampling
Urine
Urine should be collected in any case in which the complainant reports within the 
first 120 hours (5 days) after the alleged assault. While in reality many of the drugs 
listed in annex 1 may have been eliminated from urine in less than 120 hours, a 
few may remain at low concentration.
A minimum of 50 ml of urine should be collected in at least two sterile containers 
(no preservative needed) and stored at 2-8 °C. If it is not possible to analyse samples 
within 24 hours, it is advisable to store the samples in a freezer (–18 °C). Unused 
samples should be stored in a freezer in case further analysis is requested for at last 
12 months.
Whole blood
Blood should be collected in addition to urine, preferably within 48 hours of the 
alleged incident. Blood sampling should be performed with disposable syringes; the 
use of ethanol or other solvents with volatile fractions should be avoided in 
skin  disinfection. At least two 5 ml samples should be collected in blood tubes 
containing compounds such as NaF and potassium oxalate (recommended concentra-
tions for NaF 2.5 g/l and potassium oxalate 2 g/l) to prevent degradation and clotting 
with one sample used for analyses and the other retained in case of a need for a 
defence analysis. The blood samples should be refrigerated (at 2-8°C) as soon as 
possible. If it is not possible to conduct analysis within 24 hours, it is advisable to 
preserve the sample by storage in a freezer (after separating the plasma).  Furthermore, 
it is advisable that sample residues are stored in a freezer (–18 °C) in case further 
analyses are requested at a later date. In cases where blood plasma may need to be 
separated by centrifugation from blood cells prior to analysis, the  separation should 
be done before the freezing of whole blood.
It should be noted that the timeframes provided for detection of drugs in urine and 
blood are general guidelines and that many drugs will no longer be detectable in 
conventional samples such as urine, four or five days after ingestion.
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Head hair
In cases of late reporting of the alleged assault or if chronic exposure to a drug 
must be assessed, head hair should be collected at least four weeks after the alleged 
assault. At least two hair samples (thickness of a pencil) should be cut as close to 
the scalp as possible (see the figure 1 in annex 5). It is very important that hair is 
sampled in a strict manner by properly trained personnel. A sampling protocol is 
given in annex 5. In cases of a shaven head, pubic, axillary, torso or leg hair may 
also be collected for analysis, although the interpretation of the quantitative results 
in these cases remains very difficult.
When segmental analysis is not possible (if only axillary, torso or leg hair are avail-
able), analysis could be eventually limited to a qualitative analysis, because the 
growth rate is not well established, as happens in head hair. Consequently, a positive 
result in these type of hair samples indicates that the alleged victim consumed the 
compound at any time, but not necessarily at the time of the assault. 
Hair samples should be stored at room temperature, in a dry environment protected 
from light. 
Other biological samples
In some cases, vomit from the scene of the alleged assault or from the clothes of 
the complainant may be a useful specimen. If a drug is not fully absorbed before 
vomiting occurs, the drug may be detected at relatively high amounts in a vomit 
stain. If collected, vomit or a vomit stain should be stored preferably frozen. 
3.4. Other samples
If the scene of the alleged assault is searched, cups, drinking glasses, bottles, con-
tainers and liquids that may contain residues of drugs should be collected and 
submitted for analysis. Other items of evidence that could prove useful to the inves-
tigation include plates, foods, pharmaceutical products and prescriptions for medi-
cines. Photographic/video (cameras, video recorders) and electronic evidence from 
computers may also prove useful to the case as there have been several instances 
when the perpetrator(s) have recorded the assault. For trace evidence, clothing, sheets 
and bedding, sexual devices, condoms, etc. should be collected with the classical 
precautionary measures for DNA analysis. 
Police and crime scene investigators are normally trained to collect such evidence. 
Care should be taken that scene residues are packed individually in order to avoid 
cross-contamination of biological samples, especially if volatile compounds are 
implicated in the alleged assault.
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Detection of DFSA and other DFC related substances may be a very demanding 
task requiring highly sensitive and selective analytical techniques in an appropriately 
equipped and staffed laboratory. Practical issues which need to be considered in 
establishing an analytical screening procedure for biological specimens (blood, urine 
and hair) for a wide range of substances related to these cases include sample size, 
speed of analysis, sensitivity and specificity of the methods. 
The outcome or results of analysis of substances in urine may depend on the 
 analytical method used. For example, many immunoassays will not detect all the 
known benzodiazepines. In addition, exposure to some benzodiazepines may not be 
detected after 2-3 days due to the typical high detection limits of immunoassays. 
In contrast, the use of some liquid chromatography-mass spectrometry/mass spectro-
metry (LC-MS-MS) methods may allow for the detection of benzodiazepines for 
four days or longer after ingestion of a dose likely to cause incapacitation. 
False negative results due to the use of insufficiently sensitive methods may dissuade 
further investigation of the allegations and might discourage the victim from taking 
the matter further. Subsequently, immunoassays and enzymatic techniques, which 
have high detection limits, should be avoided. In case sufficient sample is available 
to permit further analyses, these techniques can be employed for preliminary screen-
ing, but very cautiously. It must also be recognized that a negative result may be 
due to insufficient sensitivity and that a positive result requires confirmation with a 
more selective technique. It must be ensured, when employing a preliminary screen-
ing technique, that a sufficient sample amount is available for further and confirma-
tory analyses. 
In case of late sampling or use of techniques with low sensitivity or poor specificity/
selectivity, the collection of larger sample amounts, preferably combined with a 
more efficient extraction of the analyte, or with concentration of an extract before 
chromatographic analysis, should be considered. 
4.1.  Substances encountered in DFSA 
and other DFC cases 
The drugs used in DFSA and other DFC have one or more of the following proper-
ties: they can cause sedation, anterograde amnesia, are odourless and tasteless, dis-
solve readily in alcoholic or other beverages, are fast-acting (within 30 minutes or 
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so of administration), have a generally short plasma half-life (a few hours) and 
generally require a low dose to be effective (exceptions include ethanol, GHB, and 
GBL and related compounds).
It appears that almost any drug with mildly sedative properties may be used by a 
perpetrator. The availability of the drug to the perpetrator is a very important criteria 
to select a drug to commit drug facilitated crime. For example, over the counter 
drugs can be purchased by anyone. Prescription drugs may be available via a legiti-
mate prescription, through medical services, or they might be bought on the Internet 
or on the street.
Substances which have been encountered in DFSA and other DFC cases are listed 
in annex 1.
4.2. Procedures and analytical strategy
As in all other forensic settings, bias towards any of the parties (complainant, sus-
pected perpetrator, or others) must be avoided. Therefore, the reliability of qualitative 
and quantitative analytical findings is an essential requisite for correct toxicological 
interpretation. To this end, methods adopted in DFSA investigations should be 
 properly validated for at least the following parameters; selectivity, calibration model 
(linearity), accuracy and precision, lower limit of detection (LLoD), lower limit of 
quantification (LLoQ), and analyte stability. Further parameters that may require 
validation are recovery, matrix effects (particularly important for LC-MS techniques), 
and ruggedness (robustness).
Only validated procedures based on adequately sensitive and selective analytical 
techniques, by hyphenated chromatographic and spectroscopic techniques such as 
LC-DAD, LC-MS, LC-MS-MS, GC-MS and GC-MS-MS, should be employed 
whenever available. However, LC-MS, LC-MS-MS and GC-MS-MS methods are 
highly recommended. If this is not possible, samples should be properly stored in 
a freezer (–18 °C) and referred for analyses to a specialized laboratory. 
The confirmation of a compound’s identity is an essential requisite in the forensic 
setting. In this regard, it must be recognized that hyphenated chromatographic and 
mass spectroscopic techniques provide, by definition, two sets of analytical data on 
the compound (retention behaviour and mass spectral data) that are sufficient for a 
proper confirmation for forensic purposes.
Quantification in blood, and for some substances also in urine (for example alcohol, 
GHB), should be performed whenever possible in order to make inference on the 
time of administration, the magnitude of the dose, and on the likely incapacitating 
effect of the drug. However, it must be stressed that these aspects of interpretation 
should be approached with extreme caution owing to the many factors involved. In 
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suspected DFSA a broad spectrum screen should be applied even if a single com-
pound is strongly suspected or detected. Any compounds identified in urine should 
be looked for and measured in blood, if an appropriate sample is available.
The analytical strategy to be adopted depends on the time of sampling in relation 
to the alleged incident and on the specimen(s) available. Higher concentrations and/
or longer detection times (typically up to 120 hours) usually apply to urine, although 
metabolites also need to be detected in this matrix. Parent compounds can be 
detected in blood for a short period of time (usually not longer than two days). 
Whenever urine and blood are not available or are sampled too late, consideration 
should be given to the detection of the parent compound in a hair sample collected 
at least four weeks after the event. It should be borne in mind that the detection of 
metabolites in hair may be useful for differentiation between external contamination 
and use.
Annex 2 lists the substances that should be first targeted in the analysis of urine, 
with minimum required performance limits (MRPL). Parent drugs and target analytes 
(metabolites) are included. 
4.3. Analytical methodology
Urine and blood analysis
The following techniques are recommended for urine and blood analysis: 
 " Volatile substances—the analysis can be achieved by head space gas 
 chromatography with either flame ionization detection (HS-GC-FID) or 
with mass spectrometry detection (HS-GC-MS); 
When headspace GC is used as the identification and detection method, 
special attention should be paid to the choice of conditions for sample 
preparation (sample pH, ionic strength, phase ratio, HS sample volume, 
incubation time and temperature), the GC oven-temperature programme and 
column specifications (polarity, film thickness) in order to optimize 
 sensitivity and selectivity.
When classical headspace equipment is not available, solid-phase micro 
extraction (SPME) is an alternative. Different SPME fibre types allow the 
adsorption of volatile and semi-volatile compounds onto the fibre, from which 
they are thermally desorbed in the GC injector. However, this technique 
requires a practical experience, particularly in DFSA and other DFC cases.
 " Non-volatile organic compounds—Screening for drugs, metabolites and other 
non-volatile organic compounds should be performed using techniques able 
to acquire the full-scan spectrometric (MS) and spectroscopic (UV-Vis) data 
of the chromatographic eluate with a sufficient scan speed. Further, 
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comparisons should be made between unknown spectra and spectra obtained 
from authentic reference standards. The use of high resolution mass- 
spectrometry (HR-MS) for the identification of unknowns by accurate 
 measurement of their mass-to-charge ratio and isotope pattern, if any, is also 
a viable alternative. Whatever the analytical technique adopted, its limitations 
(for example poor performance of polar and high molecular weight com-
pounds for GC, or on thermolabile compounds) must be taken into the 
consideration. 
Target analysis for medicinal drugs and drugs of abuse is recommended by 
GC-MS and LC-DAD or, if available, LC-MS-MS. In such cases, the use 
of methods optimized for the target analyte is very useful. However, a 
general screening method by GC-MS, combining derivatization and 
 comparison with a recent spectra library may help to identify low levels 
of specific metabolites. But as samples are most often collected late, very 
low concentrations of the substances are expected: hence it is highly 
 recommended to use LC-MS-MS or GC-MS-MS due their higher sensitivity 
and selectivity.
 " Ethanol should be analysed by gas chromatography with flame ionization 
detection by direct injection (GC-FID) or head space (HS-GC-FID).
The detection of ethanol conjugated metabolites (ethylglucuronide, ethyl 
sulfate) by LC-MS/MS or, after derivatization, by GC-MS may be consid-
ered in order to confirm or exclude the ingestion of alcoholic beverages 
when alcohol is not detected in blood or urine.
Hair analysis
The following techniques are recommended for hair analysis:
 " GC-MS, GC-MS-MS and LC-MS-MS for illicit and prescription drugs
 " LC-MS-MS for hypnotics, benzodiazepines and benzodiazepine-like drugs
 " GC-MS-MS (or LC-MS-MS) for GHB and cannabinoids
If hair analysis has to be performed, preliminary appropriate washing of the sample 
is mandatory in order to minimize the risk of surface contamination. The washings 
should also be analysed. Hair segmentation is highly recommended to differentiate 
between only one and chronic consumption.
Recommendations for sample preparation
Sample preparation is an essential step of any analytical procedure, especially when 
high sensitivity is required. Adequate sample preparation results in an increase in 
method sensitivity and selectivity and can reduce matrix effects. Even when highly 
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selective detectors such as MS-MS or HR-MS are adopted, the beneficial impact of 
sample preparation should not be disregarded. On the other hand, artifact formation, 
loss of analyte or extract contamination should always be considered during method 
development.
Hydrolysis
Glucuronidation, a conjugation reaction involving the human UDP-glucuronosyl-
transferase (UGT) family of enzymes, plays an important role in the metabolic fate 
of many drugs. The enzymatic hydrolysis of urine may be required to ensure the 
detection of compounds and/or metabolites excreted as conjugates (unless reference 
standards of the conjugates are available). 
Although enzymatic hydrolysis may be time-consuming, it has advantages of pro-
ducing cleaner samples for analysis. The milder conditions result in better analyte 
stability during the hydrolysis process and thus reduce artifact formation. Different 
types of enzymes are commercially available, but the most frequently used are 
b-glucuronidase from E. coli or Helix pomatia, combined with arylsulfatase. 
Sample procedure for the enzymatic hydrolysis of glucuronides
To 1 ml urine, add a suitable internal standard (as a glucuronide) in 
1-2 ml of a suitable buffer (pH 5.2). Add b–glucuronidase (approx. between 
1 000 and 20 000 units per ml urine) and arylsulfatase, if required. Incubate 
at 37°C overnight (approx. 16 h) or at least 90 minutes at 50°C. After 
incubation, adjust the pH of the solution appropriately for liquid-liquid or 
 solid-phase extraction.
Chemical (for example with strong acid) hydrolysis may also be used, but it results 
in a loss of selectivity owing to degradation of the compounds of interest (for 
example for benzodiazepines). However, it can be considered as a viable, cheap and 
rapid alternative for specific analytes when their stability under hydrolysis conditions 
has been assessed.
Extraction
The extraction of analytes from a sample is of analytical importance and usually 
results in increased sensitivity and selectivity/specificity. It can be performed by 
liquid-liquid extraction (LLE) or solid phase extraction (SPE). 
LLE exploits the relative affinity for, or partitioning of the analyte between two 
immiscible liquid systems, usually an organic solvent and an aqueous buffered solu-
tion. The process is based on well-defined thermodynamic relationships and has a 
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wide dynamic range. LLE has advantages of being fast, inexpensive and efficient, 
and works especially well with urine. However, LLE may involve high solvent consump-
tion and care must be taken to avoid the formation of emulsions during extraction.
Extraction from aqueous samples (for example urine, blood) should be performed 
at an appropriate pH value with reference to the pKa of the target analytes. For 
screening purposes, extraction should be performed at various pH-values (for 
 example pH 2-3 and pH 8-9). Saturation with neutral salts (for example NaCl) is 
recommended. A phase ratio (organic/aqueous) of 1:2 should be the aim in order 
to avoid co-extraction of a large amount of interferences. 
SPE may be used as an alternative to liquid-liquid extraction. When appropriate 
sample dilution has been used, it will allow continuous flow of the specimens 
through the SPE cartridges and avoid clogging. SPE, which is suitable for both large 
and small sample volumes, typically requires use of less solvent than LLE and 
results in high extraction efficiency. The exploitation of the relative affinities of drug 
substances for the wide range of available solid phase chemistries and mechanisms 
(for example hydrophobic/hydrophilic interactions, ion-exchange, immuno-affinity) 
and appropriate selection of sample loading, washing or eluting buffers/solvents by 
the analyst results in cleaner and highly concentrated samples for analysis. This 
results in increased sensitivity and selectivity.
The availability of highly selective analytical techniques, such as those obtained for 
hyphenation of chromatographic and spectroscopic methods for example LC-MS, 
has led to the development of methods for “direct analysis” for certain analytes by 
means of the so-called “dilute and shoot” technique. Although this practice brings 
many advantages in terms of avoiding the possible drawbacks of sample preparation 
and of increasing the sample throughput, its application should be preceded by a 
thorough method validation, especially with reference to matrix effects.
Derivatization
Gas chromatography (GC) is a technique used in the detection and identification of 
organic compounds that are volatile and stable up to 350°C or so. The volatility of 
the desired analyte may be inherent (for example ethanol) or improved with 
 derivatization. The process of derivatization increases the spectrum of substances 
that can be analysed by GC and can be performed prior to, or during the extraction. 
An important prerequisite for this approach is the availability of reference data 
(for example retention times, mass spectra) for the corresponding derivatives of 
toxicologically relevant compounds. 
Silylating agents, for example TMCS (trimethylchlorosilane), but also BSTFA or 
MSTFA, are able to react with a wide spectrum of functional groups as hydroxyl-, 
carboxyl- , and amino-groups to produce volatile products suitable for GC analysis. 
This makes the process particularly suitable for systematic toxicological analyses 
(STA) and the most used in GC analysis. Silylating reagents have an added advantage 
4. Analytical considerations 19
of not requiring removal of excess reactant prior to GC analysis. However, silyl 
derivatives are very sensitive to moisture so the reaction should occur under strict 
anhydrous conditions. Moreover, deposition of silica at the detector may be a problem.
Alternative derivatization procedures involve acetylation of compounds with amine 
and hydroxyl functional groups using acetic anhydride, and methylation of acidic 
groups using iodomethane. Derivatization procedures with mixtures of perfluorinated 
alcohols and anhydrides are widely applied, as well.
Example procedure for derivatization by silylation 
To the dry residue after solvent extraction, add 20 µl of BSTFA containing 
1% TMCS (this reagent is ready-to-use commercially available, and the 
manufacturers provide information of its potential use). Mix by vortex. 
Incubate at 80°C for 15 minutes.
Example procedure for derivatization by methylation 
Prepare a solution of TMAH at 0,5g/ml in water (may be kept for six 
months at 20°C). Extemporaneously, add 100 µl TMAH to 2.0 ml DMSO. 
Add 200 µl of this reagent to the dry residue after solvent extraction. Mix 
by vortex. Leave for 2 minutes at laboratory temperature. Add 50µl 
iodomethane (work under extractor hood), vortex, and incubate at room 
temperature for 15 minutes. Stop reaction with 200 µl 0.1N HCl.
Best practice recommendations for laboratory analysis
Fully validated procedures according to internationally accepted standards should 
be available and employed for qualitative and quantitative analysis. Appropriate 
internal standards should be adopted. The use of stable isotope labeled internal 
standards (deuterium/carbon 13) is encouraged for mass spectrometric techniques.
The following recommendations should be considered by the laboratory when 
 analysing specimens from suspected DFSA cases:
 " Measurement of blood and urine concentrations must be done from the first 
available biological specimen; back calculation may be of some help if any 
alcohol is found. If ethanol intake is suspected or should be excluded, but 
is not detected in the blood and urine samples due to late sampling, the 
determination of conjugated ethanol metabolites may be performed.
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 " Enzymatic hydrolysis rather than acidic hydrolysis should be used for 
 general purpose screening. It also allows lower detection limits in the 
 benzodiazepine assays.
 " Particular effort should be devoted to the detection of benzodiazepines and 
benzodiazepine-like drugs (Z-drugs) in urine, because of their frequent 
involvement in these cases. Different methods have been used successfully 
(for example GC-MS after hydrolysis, solvent extraction and derivatization; 
NCI-GC-MS after hydrolysis and SPE extraction; NCI-GC-MS-MS).
In hair analysis, deuterated analogs of the compounds under study have to 
be added at a low enough concentration to avoid the isotopic contribution.
 " When using an immunoassay for screening, the limits of sensitivity of this 
analytical technique should be recognized. When the immunoassay is 
devoted to a group of compounds (for example benzodiazepines), the limits 
of detection for the most common compounds and/or metabolites should 
be specifically assessed, noting that the cut-offs proposed by the manufac-
turer may be too high for their application in DFSA investigations. How-
ever, lower cut–off levels may be applied when proper revalidation of the 
method is performed.
 " In general, the use of immunoassays in DFSA cases is discouraged. If immuno-
assays are used in a laboratory, sensitive chromatographic assays are absolutely 
mandatory for screening and confirming drug classes. 
Example of an analytical strategy
Alcohol determination in blood and urine 
Quantitative value of ethanol should be determined in blood and urine samples. If 
the analysis for ethanol is negative, particularly in cases of late sampling, the deter-
mination of ethylglucuronide and sulphate may be considered.
Hydrolysis of urine 
Urine aliquot should be submitted to enzymatic hydrolysis before extraction for 
non-volatile organic compounds.
Extractions
Different solvents may be employed and each laboratory has to improved the best 
suitable after testing in the usual conditions of the laboratory.
1. Extraction from blood and urine: 
 (a) GHB: neutral extraction
 (b) Cannabinoids: acidic extraction 
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 (c)  Other psychoactive substances: LLE at different pH values of the 
sample for acidic/neutral and basic analytes
2. Extraction from hair:
 (a) GHB: after digestion in NaOH
 (b) Barbiturates: acidic extraction
 (c)  Other psychoactive substances: LLE after incubation in Sörensen buffer
 (d)  Cannabinoids and amphetamines: LLE after digestion with NaOH 
and derivatization 
Instrumental analysis
1. GC-MS
 (a)  Columns: for a general screening, classical non-polar 5% phenyl 
95% methylpolysiloxane capillary columns are a good compromise.
 (b)  Detectors: when electron impact ionization (EI) is used, a deriva tiza-
tion step may be required. Negative chemical ionization (NCI) or 
positive chemical ionization (PCI) increases sensitivity and specificity.
2. LC-MS-MS
 (a)  Columns: most of the screening methods are based on reversed and 
normal phase columns. With the large number of different columns 
on the market, it is important for a laboratory to evaluate the column 
of interest under their own unique conditions. 
  (b) Detectors: 
		Atmospheric pressure ion sources, either electrospray (ESI) or 
atmospheric pressure chemical ionization (APCI) may be used. 
The former is preferred for polar analytes, the latter for thermally 
stable and less polar analytes.
	 If MS-MS is not available, fragmentation can be obtained before 
the MS analyser by collisionally induced dissociation (CID). 
However, spectra heavily contaminated with chemical noise are 
typically obtained.
	 MS-MS detection should be adopted whenever available owing 
to its better selectivity. Triple quadrupole instruments offer more 
versatility and better quantification performance than ion-trap 
instruments, although at higher cost.
3.  Examples of analytical conditions (refer to the Bibliography for fully 
detailed methods)
 (a) GHB in blood and urine:
	 Extraction is performed in acidic conditions with ethyl acetate, 
after adding GHB-D6 as an internal standard; 
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	 Detection is performed by GC-MS, after derivatization with 
BSTFA.
 (b) GHB in hair:
	 Extraction is performed with ethyl acetate after incubation in 
NaOH at 80°C;
	 Detection is performed by GC-MS-MS, after derivatization with 
BSTFA.
 (c). Cannabis in blood:
	Extraction is performed with hexane/ethylacetate (2/1: vol/vol);
	 Detection is performed by GC-MS-MS, after derivatization with 
BSTFA.
 (d) Cannabis in hair:
	 Extraction is performed with hexane/ethylacetate (2/1: vol/vol) 
on hair after incubation in NaOH;
	 Detection is performed by GC-MS-MS, after derivatization with 
BSTFA.
 (e)  Other psychoactive substances and street drugs, in blood, urine and hair:
	 Extraction is performed with liquid-liquid extraction (LLE) for 
blood and urine, and by hexane/ethylacetate (2/1: vol/vol) in hair, 
after digestion with NaOH at 80°C. Extraction by sonication/
incubation with methanol is a better choice for labile compounds 
as opiates and cocaine. Filtration is needed.
	 Instrumental analysis is performed by LC-ESI-MS-MS with a C18 
column, using SRM mode and PCI (except for barbiturates: NCI).
A number of source parameters have to be specifically adjusted and optimized for 
each analyte on a LC-MS instrument in use in the laboratory, as they might vary 
significantly between different manufacturers (ion source temperature, gas flows, frag-
mentor voltage, collision energy). Scan speed should be adjusted to obtain a minimum 
of 10 scans across the analyte peak to obtain an adequate quantification performance. 
Identification should be performed by monitoring at least two specific reactions 
(involving the pseudomolecular ion or a high mass fragment as precursor and avoiding 
poorly specific product ions, such as fragments resulting from the loss of water).
The linear dynamic range should be assessed. These may be relatively narrow, typi-
cally 10-500 µg/l in blood or urine and 100-500 pg/mg in hair. Matrix effect and 
ion suppression must be tested. 
Due to the frequent upgrades of the LC-MS-MS (or GC-MS-MS) instruments by 
the suppliers, each laboratory has to optimize its own methodology: for example, 
one can have one method for neuroleptics and antidepressants and another for 
 benzo diazepines. The aim is to obtain the best sensitivity and to achieve the analysis 
(and interpretation) as quickly as possible: solving DFSA and DFC cases can be 
considered as an emergency, in a judicial point of view.
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Example of a flow chart for the toxicological analysis
The laboratory should have documented procedures for the overall process of  handling 
DFSA cases. Below is an example of a strategy on how to handle toxicological 
analysis in DFSA cases. 
Collect info about case 
Does the case meet 
your laboratory’s case 
acceptance policy?
Conduction targeted 
analysis on suspected drugs 
and related metabolites
Is particular 
drug suspected?
Is a useful* urine
specimen available?
Yes
Screen urine
Confirmed significant 
findings?
Analyse for confirmed
drug and/or metabolites
in additional 
useful specimens
*Urine < 120 hours (5 days), blood < 48 hous (2 days) 
after alleged assault
Decline the case or send 
to another laboratory
Conduct analyses for
“routine” DFSA drugs
and metabolites
Screen blood
Is a useful* blood
specimen available?
Report findings
Should any other routine
or non-routine DFSA
drug screenings be
implemented?
Screen other biological
specimens (segmental hair
analysis after 4-6 weeks)
Yes
Yes
Yes
No
No
No
No
Yes
No
No
Yes
Reference: LeBeau, M. A.: Laboratory management of drug-facilitated sexual assault cases; Forensic 
Science Review, 22:113;2010.
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4.4. Reference compounds
The availability of reference standards for parent and/or metabolites is a prerequisite 
for qualitative and quantitative analysis. Certified reference materials (CRMs) can 
be used if available. CRMs have one or more property values are certified by a 
procedure, which establishes their traceability to an accurate realization of the unit 
in which the property values are expressed. Each certified value is accompanied by 
an uncertainty at a stated level of confidence. 
In the absence of CRMs, commercial reference standards should be used. These 
reference standards/materials should be sufficiently pure to make them suitable for 
calibration of an apparatus, the assessment of a measurement method, or for assign-
ing values to materials. These do not provide formal traceability but are useful and 
less expensive alternatives for initial method development
The exchange of analytical standards (and of analytical data as well) between laboratories 
should be encouraged, in accordance with national and international legislation. 
4.5. Minimum required performance limits (MRPL)
In order to ensure that all laboratories report the presence of DFSA related sub-
stances in a uniform way, a minimum routine detection capability for testing methods 
should established. While it is inevitable that some laboratories will be able to 
identify a wider range or lower concentrations of substances than other laboratories, 
it is also recognized that minimum required performance levels (MRPL) must be 
met by all laboratories dealing with these cases. 
MRPLs are technical performance parameters with which all laboratories should 
comply when testing for the presence of a DFSA related substance. They neither 
represent a threshold, nor a limit of detection (LLoD) or of quantification (LLoQ). 
Positive results may still be obtained with procedures with LLoDs below the estab-
lished MRPL values. On the other hand, false negatives may result from the adoption 
of analytical methods with LLoDs above the proposed MRPLs. 
Substances which should be first targeted in DFSA analysis with minimum required 
performance limits are listed in annex 2.
4.6.  Factors out of the control of the 
forensic toxicologist
The validity of laboratory analysis or data is inextricably linked to the quality 
control measures adopted from the collection of evidence, through documentation, 
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transportation and storage up to the receipt of samples by the forensic toxicologist. 
Some of these factors, which are out of the control of the forensic toxicologist, 
include the clinical examination, collection and storage of evidence by the law 
enforcement/health professionals, and preliminary screening where applicable.
One of the most common shortfalls in clinical examination at the emergency unit/
forensic emergency unit is that the clinician may not be aware of the possibility 
that a DFSA may have occurred. This could result from the fact that the victim 
may not be aware that a drug has been placed surreptitiously in his/her drink, or 
that the victim does not want to disclose his/her voluntary consumption of an illicit 
drug prior to the suspected incident. Blood and urine should be collected immedi-
ately by the clinician who should note the date and time of the collection. It is also 
the responsibility of the clinician to collect a sufficient volume of blood and urine. 
Finger-prick blood specimens and buccal swabs are of poor evidentiary value and 
similarly the collection of hair on the day of the suspected event. 
Sample storage conditions at the hospital are also not under the control of 
the forensic toxicologist. A specific person should be tasked with the responsibility 
of storing the samples in a secured environment, under temperature-controlled 
conditions.
The importance of ongoing communication between the toxicologist and the 
 investigating police team should be emphasized. This enables the results to be dis-
cussed, provides an opportunity to request further information (if needed) and to 
establish whether there is a legitimate reason for the presence of any drugs detected 
in case samples.
4.7.  Staff skill requirements and 
equipment considerations
The complex nature of DFSA cases and the concomitant analytical challenges neces-
sitates well-trained scientists and sufficiently equipped laboratories. 
Staff should have skills in the fundamental aspects of analytical chemistry, forensic- 
and clinical toxicology as well as in pharmacology, including a sound background 
in drug metabolism and pharmacokinetics. The analytical chemistry training should 
include knowledge and use of hyphenated techniques such as chromatography-mass 
spectrometry (GC-MS, LC-MS and Tandem MS technologies), sample preparation 
and extraction procedures applicable to trace analysis, method validation, data 
 handling and reporting of results. The respect for human dignity and confidentiality 
of personal information are essential attributes and should be part of their daily 
operation. Staff should have the ability to interact with investigating officers and 
with the criminal courts.
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In view of the financial outlay required to fully equip a forensic toxicology labora-
tory in order to fulfil requirements mentioned above, it is recommended that analysis 
be directed to designated laboratories, which have the analytical capacity to reach 
the minimum required performance limits (MRPL). Adequate sampling, evidence 
collection and storage should still be performed at a local level to ensure that the 
results produced by the regional laboratories are scientifically accurate and valid.
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As stated earlier, a negative toxicological finding does not exclude the use of a drug 
in a possible DFSA case. Negative findings may be due to:
 " Late sample collection resulting in drug and/or metabolite concentrations 
below the MRPL of the laboratory. Note that the table in annex 3 shows 
the half lives (T1/2) for some drugs. This may be useful in evaluating the 
time that a drug would be expected to remain in the blood or urine after 
ingestion and may assist in the estimation and verification of the time at 
which the complainant claims to have lost his (her) consciousness.
 " Use of a substance that is unknown to the laboratory and/or which is beyond 
its analytical capability (for example new “designer drugs” or substances 
showing high-potency at low concentrations).
 " Breaking down on storage for some drugs (for example zopiclone and new 
drugs such as methcathinones). If it is not possible to analyse samples 
within 24 hours, freezing samples (–18 °C) as soon as possible is the best 
option to avoid this degradation. 
Any medication or procedures used in treatment of the complainant should be con-
sidered in interpretation. Concomitant administration of a diuretic drug for instance, 
may result in urine dilution causing the concentration of the suspected compound 
to be below the MRPL sooner than would be the case if a single compound were 
administered. Co-administration of alcohol may have a profound effect on the 
pharma cokinetics and pharmacodynamics of the administered drug. Therefore, 
results should be reviewed in context of the entire investigation and case history. 
5.1. Urine
A positive identification in urine is normally sufficient proof that the victim was 
exposed to a drug within a period of one to five days before the sample was col-
lected. It should be noted that the period of detection depends on the substance, as 
well as the dose that was administered. The practice of correlating the urinary 
concentration at the time of sampling with the dose and effect of the drug at the 
time of exposure is discouraged. 
Due to the endogenous nature of GHB, caution must be taken in the interpretation 
of positive findings. GHB concentrations have been shown to increase in vitro in 
urine samples during the storage. Therefore, the actual recommended cut-off 
 concentration for endogenous GHB in urine is 10 mg/l to help to distinguish 
 endogenous from exogenous GHB. 
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5.2. Blood
A positive finding in blood may be proof of an exposure to a drug within a shorter 
time period compared to urine (usually less than 48 hours). Blood concentration 
may provide information on the possible pharmacological effect at the time of the 
alleged incident. A concentration of a drug in blood, along with pharmacokinetic 
information may be used to predict and correlate the symptoms described by the 
victim. Anterograde amnesia and/or unconsciousness may result in difficulty to 
 accurately estimate the time of the suspected incident.
Finding GHB in the blood may help for the interpretation of the results obtained 
in the urine. Like in urine, GHB concentrations have been shown to increase in 
vitro in blood samples during the storage. Therefore, researchers have suggested that 
an adequate cutoff for GHB as high as 2 mg/l if blood is collected aseptically and 
stored at +4°C. GHB aciduria is a rare genetic disorder (succinic semialdehyde 
dehydrogenase deficiency) in which the endogenous GHB levels in blood and urine 
of its patients are increased. 
One has to differentiate endogenous production from exogenous administration and 
the strongest interpretation of any GHB findings can be made when you have 
 complimentary findings in urine and blood.
5.3. Hair
A positive finding in hair may provide proof of an exposure during the growth 
period analysed. Segmental analysis is important to provide information on the 
appropriate time period during which the suspected crime occurred. Segmental hair 
analysis can provide information as to whether the substance was taken regularly 
before the alleged incident or if the substance had been ingested only in a short 
timeframe that corresponded to the moment of the incident. It is important that 
segmental hair analysis results be considered in the context of other evidence to 
support the case. The mean growth speed of head hair 1.0 +/- 0.2 cm per month is 
commonly used. However, the growth speed for some hair could be as low as 0.6 cm 
per month or up to 2 cm per month.
Special attention has to be given to the hair analysis of GHB. As GHB is an endog-
enous compound, normal levels of endogenous GHB in each individual vary. The 
strand of hair has to be cut in 5 to 10 small segments (0.3 to 0.5 cm long) and 
each segment analysed for GHB in order to identify if one segment has GHB con-
centration 10 times higher than the others, suggesting possible administration of 
exogenous GHB. 
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Information available on DFSA and other DFC is primarily based on anecdotes and 
limited data are available on its frequency and current trends. Effective policies to 
address the increase in DFSA and other DFC require the availability of accurate 
and reliable data and information, including the types of substances used and 
 prevalence, in other to define national and regional trends. The required data needs 
to have a high degree of certainty and must be the result of cooperation between 
all the agencies involved: the police, the medical personnel, the forensic toxicologist 
and the judicial authorities. The data collection procedures used in some countries, 
for example surveys, responses to charity helplines, governmental statistics, data 
published by scientists in meetings, need to be standardized to facilitate  comparability 
of data.
Based on limited available data, it would seem that most of the substances implicated 
in DFSA and other DFC cases (except alcohol) are under international control and 
scheduled under the United Nations Single Convention on Narcotic Drugs, 1961 
and the Convention on Psychotropic Substances, 1971. However, psychotropic 
 substances such as GBL and some antihistamines used in sexual assault cases, 
remain outside international controls, although controls exist at national level in 
some countries. Such disparities in national and regional legislations allow trafficking 
of psychoactive substances through different countries, often via the Internet and 
courier, and make it difficult to obtain accurate data on the nature and the extent 
of the problem.
While expert perception points to an increase in the number of DFSA and other 
DFC cases, constraints exist with regard to the availability and collection of data. 
Victims may be unwilling to go to the police and/or the hospital to be examined. 
Police records in some countries can, in principle, provide some information. But 
they cannot comprehensively describe the phenomena since DFSA are often not 
reported to the authorities and, when they are, they may be classified under more 
generic offenses (such as rape). The actual prevalence of sexual assaults, particularly 
DFSA cases, is underreported and only very little information and statistics are 
available. Forensic laboratories may not always report their data on DFSA and 
governmental health organizations do not collect such data in all countries. In 
 recognition of the difficulties in obtaining accurate data on the subject, the Com-
mission on Narcotic Drugs (CND) in its resolution 53/7 (2010) invited member 
states and regional organizations to promote research into the administration of 
psychoactive substances for sexual assault or other criminal purposes with a view 
to measuring the extent of the phenomenon, ascertaining the modi operandi of 
assailants and identifying the psychoactive substances used, whether under 
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international control or not. The Commission further noted that it is essential to 
highlight the problem and that an improvement in national capacity to collect data 
is needed.
In order to support countries trying to enhance the quality and availability of data 
on DFSA and other DFC, there is the need to develop standards on how to collect 
the data through population-based surveys and administrative recording systems on 
crime and criminal justice. Victim surveys are potentially a good tool to collect data 
on DFSA and other DFC as they reach out to the potential victims. Standard 
 guidelines should be developed to improve the current recording system for crimes 
in order to ensure that DFSA and other DFCs are properly recorded and the 
data analysed. 
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Annex 1.  Actual substances encountered in DFSA 
and other DFC cases
GHB
GHB, GBL, 1,4-BD, valerolactone
Benzodiazepines
Alprazolam 
Bromazepam 
Chlordiazepoxide 
Clobazam 
Clonazepam
Clorazepate
Clotiazepam 
Cloxazolam
Diazepam 
Estazolam 
Flunitrazepam 
Loprazolam 
Lorazepam 
Lormetazepam
Medazepam
Midazolam 
Nitrazepam 
Nordazepam (=nordiazepam)
Oxazepam
Phenazepam 
Prazepam 
Temazepam 
Tetrazepam
Triazolam 
Z-drugs (hypnotics)
Zaleplon
Zolpidem 
Zopiclone 
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Antihistamines and others 
Antihistamines
Brompheniramine 
Cetirizine 
Chlorpheniramine 
Cyclobenzaprine
Diphenhydramine 
Doxylamine 
Hydroxyzine 
Niaprazine
Others
Aceprometazine
Alimemazine 
Amitriptyline
Chloral hydrate
Clonidine
Clozapine
Cyamemazine 
Dextromethorphan 
Haloperidol
Meprobamate
New antidepressants
Oxomemazine 
Valproic acid
Barbiturates
Amobarbital
Barbital
Pentobarbital 
Phenobarbital
Secobarbital
Opiates and opioids (licit narcotic analgesics)
Codeine 
Dihydrocodeine 
Hydromorphone
Methadone
Morphine
Oxycodone
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Street drugs and traditional drugs of abuse 
Cannabinoids 
Natural (THC)
Synthetic cannabinomimetics (Spice, etc.)
Opiates
Heroin 
Morphine
Cocaine
Cocaine and crack cocaine
Amphetamines
Amphetamine
PMA
MBDB 
MDA
MDEA
MDMA
Methamphetamine
Others
Atropine 
Ayahuasca 
Cathinone and cathinone derivatives
Hallucinogenic mushrooms
Kawa-kawa 
Ketamine
LSD
Mescaline 
Phencyclidine
Piperazine group
Poppers
Salvinorine A
Scopolamine
Ethanol (alcohol)
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Annex 2.  Substances that should be targeted 
for in the analysis of urine, with 
minimum required performance limits 
(MRPLs), including parent drugs 
and metabolites
This list is a comprehensive list and each laboratory needs to select the substances 
which are most commonly used in their region and/or country.
Reference: Recommended Maximum Detection Limits for common 
DFSA drugs and metabolites in urine samples, Drug-Facilitated Sexual 
Assault Committee,  Society of Forensic Toxicologists (SOFT).
Laboratories are encouraged to screen at the proposed detection limits or lower 
according to their current capacity. 
GHB
Gamma-hydroxy butyrate 10 mg/l
Benzodiazepines
Alprazolam and alpha-OH-alprazolam 10 µg/l
Bromazepam and OH-bromazepam  10 µg/l
Chlordiazepoxide 10 µg/l
Clobazam  10 µg/l
Clonazepam and 7-aminoclonazepam   5 µg/l
Clotiazepam 10 µg/l
Diazepam  10 µg/l
Estazolam  10 µg/l
Flunitrazepam and 7-aminoflunitrazepam  5 µg/l 
Loprazolam 10 µg/l
Lorazepam  10 µg/l 
Lormetazepam  10 µg/l
Midazolam  10 µg/l
Nitrazepam and 7-aminonitrazepam  5 µg/l
Nordiazepam 10 µg/l
Oxazepam  10 µg/l
Phenazepam  5 µg/l
Prazepam  10 µg/l
Temazepam  10 µg/l 
Tetrazepam 10 µg/l
Triazolam and 4-OH-triazolam  5 µg/l
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Z-drugs (hypnotics)
Zaleplon 10 µg/l
Zolpidem and metabolites 10 µg/l
Zopiclone and metabolites 10 µg/l
Antihistamines and others 
Aceprometazine 10 µg/l
Alimemazine  10 µg/l
Amitriptyline and nortriptyline 10 µg/l
Brompheniramine and desmethyl-B 10 µg/l
Carisoprodol and meprobamate 50 µg/l
Cetirizine  10 µg/l
Chlorpheniramine and desmethyl-C 10 µg/l
Citalopram and desmethylcitalopram 10 µg/l
Clonidine 10 µg/l
Cyamemazine  10 µg/l
Cyclobenzaprine 10 µg/l
Desipramine 10 µg/l
Diphenhydramine 10 µg/l
Dextromethorphan 10 µg/l
Doxepin and desmethyldoxepin 10 µg/l
Doxylamine and desmethyldoxylamine 10 µg/l
Fluoxetine and norfluoxetine 10 µg/l
Haloperidol  10 µg/l
Hydroxyzine 10 µg/l
Imipramine 10 µg/l
Niaprazine 10 µg/l
Oxomemazine 20 µg/l
Paroxetine 10 µg/l
Sertraline and norsertraline 10 µg/l
Valproic acid 50 µg/l
Barbiturates
Amobarbital 25 µg/l
Butalbital 25 µg/l
Pentobarbital 25 µg/l
Phenobarbital 25 µg/l
Secobarbital 25 µg/l
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Narcotics and non-narcotics analgesics
Codeine 10 µg/l
Dextromethorphan 10 µg/l
Dihydrocodeine 10 µg/l
Fentanyl 10 µg/l
Hydrocodone 10 µg/l
Hydromorphone 10 µg/l
Meperidine (pethidine) 10 µg/l
Methadone 10 µg/l
Morphine 10 µg/l
Oxycodone 10 µg/l
Pethidine 10 µg/l
Propoxyphene and norpropoxyphene 10 µg/l
Street drugs and miscellaneous drugs
Cannabinoids 
THC-COOH 10 µg/l
Opiates
6-mono-acetyl-morphine (MAM) 10 µg/l
Morphine 10 µg/l
Cocaine
Benzoylecgonine 50 ng/ml
Cocaine 50 µg/l
Cocaethylene 50 µg/l
Methylecgonine 50 µg/l
Amphetamines
Amphetamine 10 µg/l
Methamphetamine 10 µg/l
MBDB 10 µg/l
MDA 10 µg/l
MDEA 10 µg/l
MDMA 10 µg/l
Ketamine and norketamine 1 µg/l
Lysergic acid (LSD) 1 µg/l
Phencyclidine 10 µg/l
Piperazine group 10 µg/l
Scopolamine 10 µg/l
Ethanol 0.1 g/l
Ethyl glucuronide 100 µg/l
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Annex 3.  Half-lives (T1/2), therapeutic and toxic 
concentrations for select CNS depressants
T1/2 may be useful in evaluating the time that a drug would be expected to remain 
in the blood or urine after ingestion and may assist in the estimation and verification 
of the time at which the complainant claims to have lost his(her) consciousness.
References: Baselt R., 2011; Drummer O. H., 2001, Moffat A. C. et al, 2011.
Molecule
Therapeutic 
concentrations in 
the blood (µg/l)
Toxic concentrations 
in the blood (µg/l) T1/2 (hours)
Alprazolam 5-50 75 12-15
Alimemazine 50-400 >500  6-18
Bromazepam 80-200 300-500  8-19
Cetirizine 250-450 NA 6.5-10
Chlordiazepoxide 400-2 000 5 000 20-40
Clobazam 100-600 NA 10-20 (metab: 50)
Clonazepam 10-80 100-120 19-40
Clotiazepam 10-700 1 000-5 000 4
Diazepam 250-1 500 5 000 20-30
Cyamemazine 50-400 NA 10
Estazolam 55-100 1 000 10-24
Doxylamine 50-400 NA 10
Flunitrazepam 1-15 50 20
Haloperidol 5-40 >500 10-40
Hydroxyzine 50-90 >100 13-27
Loprazolam 5-10 NA  6-23
Lorazepam 20-250 300 12
Lormetazepam 1-25 NA 10
Meprobamate 5 000-20 000 >50 000  6-17
Midazolam 40-100 1 000-1 500 2-3
Nitrazepam 10-180 200-500 20-25
Nordazepam 200-2 000 2 000 65
Oxazepam 200-2 000 3 000 8
Prazepam 10-200 1 000-5 000 metab: 65
Temazepam 20-900 1 000 5-8
Tetrazepam 50-600 6 000 10-26
Triazolam 2-20 200 1.5-3 (metab: 4)
Zolpidem 30-300 500 1.5-4.5
Zopiclone 10-50 150 3.5-6.5
NA: data non available
metab: metabolite
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Annex 4.  Example of information collection 
worksheet for DFSA cases
Reference: LeBeau M. A.: Laboratory management of drug-facilitated 
 sexual assault cases; Forensic Science Review, 22:113:2010. 
Drug-facilitated sexual assault  
information collection worksheet
Agency: _________________________________  City: ___________________________________
Contact Person: __________________________  Phone: _________________________________
Name of Victim: _________________________  Name of Suspect (s): ____________________
Case Number(s): _________________________  Date and Time(s) of Assault: ____________
Date of Contact: _________________________  Examiner Collecting Information: ________
__________________________________________________________________________________
 1. Were any specimens collected and what were they? ___________________________
 2. When were the specimens collected (date and times)? _________________________
 3. What symptoms did the victim describe? ______________________________________
__________________________________________________________________________________
 4. Were there any witnesses? If so, how did they describe the victim? ____________
__________________________________________________________________________________
 5. How long did the victim have amnesia or was the victim unconscious? _________
__________________________________________________________________________________
 6.  Did the victim consume any alcohol? If so, how much (types of alcohol, size of 
drinks, over how many hours, etc.)? __________________________________________
 7.  Did the victim voluntarily take any drugs (recreational, prescription or over-the-
counter)? If so, which ones, how much and when? ____________________________
 8.  Did the victim urinate prior to providing any specimens? If so, approximately how 
many times? Please indicate the time of the previous urination. _______________
 9.  What is known about the suspect in regard to occupation, hobbies, drug history 
and medical history? _________________________________________________________
10. What recreational and prescription drugs does the suspect have ready access to?
__________________________________________________________________________________
11. Additional notes of interest: __________________________________________________
__________________________________________________________________________________
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Annex 5. Example of hair collection checklist
Reference: FBI Laboratory, Chemistry Unit, United States.
Collection steps for hair specimens for analysis of exposure to drugs
Hair has been used as a specimen to evaluate people’s exposure to certain drugs 
and poisons for many years. While this specimen does not allow for as comprehen-
sive a drug screen as more common specimens (for example blood and urine), it 
does allow for assessment of exposure over longer periods of time (i.e. months for 
hair as opposed to hours or days for blood and urine). For this reason, hair becomes 
a particularly useful specimen when there is a significant delay between the  suspected 
last time that exposure to the drug took place and when collection actually occurs. 
Typically, head hair is utilized. 
It is advised to wait at least four weeks after suspected drug exposure before 
 collecting the hair samples. Cutting the hair is not allowed during this period of 
time. The following steps, which vary greatly from those required to take hair 
samples for trace evidence examination, should be followed for the collection of 
hair submitted for drug testing (two hair clippings should be collected and  packaged 
separately):
Step one:  Assemble all collection materials to include: 
 " Chain-of-custody and consent forms (if applicable)
 " White envelope (letter size)
 " Evidence tape or evidence bag
 " Aluminum foil (optional)
 " Scissors
 " Twist tie
Step two: Label two white envelopes to include:
 " Name of the person from whom the hair is collected
 " Location that hair is collected from
 " Collection date
 " Name of the person collecting the hair
Step three:  Using a twist tie, secure a twist of hair (about the diameter of a pencil) 
from the crown of the head (figure 1).
Step four: Cut the hair as close to the scalp as possible (figure 1).
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Step five:  Ensure the cut hair is tightly secured with the twist tie and place into 
the white envelope. Samples may be secured with aluminum foil 
before mailing in order to retain orientation. Seal envelope. Secure 
with evidence tape or place into evidence bag.
Step six: Repeat steps 3 through 5 in order to collect a second sample.
Figure 1. Cut hair next to scalp.
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